What is the mechanism of action for Atenolol?

What is the mechanism of action for Atenolol?

• A. Inhibition of angiotensin-converting enzyme
• B. Blockade of calcium channels
• C. Decreases AV nodal conduction in supraventricular tachycardias
• D. Inhibition of platelet aggregation

Answer: (C)

Atenolol is classified as a selective beta-1 adrenergic antagonist, primarily affecting the heart. Its main mechanism of action involves blocking the beta-1 receptors located in the cardiac tissues, which leads to a decrease in heart rate, reduction in force of contraction, and ultimately a decrease in cardiac output. Additionally, by diminishing the effects of catecholamines, Atenolol decreases the conduction through the atrioventricular (AV) node, which is particularly beneficial in managing supraventricular tachycardias. Supraventricular tachycardias may result from excessive conduction through the AV node, and Atenolol's ability to decrease this conduction helps restore a more normal heart rhythm. While the other mechanisms listed relate to different pharmaceutical actions, they do not describe Atenolol's effects. Atenolol does not inhibit angiotensin-converting enzyme nor does it block calcium channels; these effects are more characteristic of other drug classes such as ACE inhibitors and calcium channel blockers. Furthermore, inhibition of platelet aggregation is associated with anticoagulants and antiplatelet agents, which do not include Atenolol. Thus, option C accurately describes Atenolol's role in decreasing AV nodal conduction specifically associated with the treatment of

Atenolol is classified as a selective beta-1 adrenergic antagonist, primarily affecting the heart. Its main mechanism of action involves blocking the beta-1 receptors located in the cardiac tissues, which leads to a decrease in heart rate, reduction in force of contraction, and ultimately a decrease in cardiac output. Additionally, by diminishing the effects of catecholamines, Atenolol decreases the conduction through the atrioventricular (AV) node, which is particularly beneficial in managing supraventricular tachycardias. Supraventricular tachycardias may result from excessive conduction through the AV node, and Atenolol's ability to decrease this conduction helps restore a more normal heart rhythm.

While the other mechanisms listed relate to different pharmaceutical actions, they do not describe Atenolol's effects. Atenolol does not inhibit angiotensin-converting enzyme nor does it block calcium channels; these effects are more characteristic of other drug classes such as ACE inhibitors and calcium channel blockers. Furthermore, inhibition of platelet aggregation is associated with anticoagulants and antiplatelet agents, which do not include Atenolol. Thus, option C accurately describes Atenolol's role in decreasing AV nodal conduction specifically associated with the treatment of